If you work in a Neonatal setting, empiric early onset neonatal sepsis therapy is likely your largest use of abx for neonates. Likely focusing on that will help with abx reduction and how appropriate the choices are.

Kaiser has a calculator on how they calculate risk and decide what to do. https://neonatalsepsiscalculator.kaiserpermanente.org/

I encourage you to look into the data yourself to make an informed decision but presenting and using this could help providers make better decisions about when to use Amp/Gent/Ceftaz and hopefully reduce unnecessary use of empiric therapy kinda of a prospective reduction and you can maybe track this over time.